These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2734311)

  • 21. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of heterozygosity in sporadic primary cutaneous melanoma.
    Healy E; Rehman I; Angus B; Rees JL
    Genes Chromosomes Cancer; 1995 Feb; 12(2):152-6. PubMed ID: 7535089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas.
    Simon D; Knowles BB; Weith A
    Oncogene; 1991 May; 6(5):765-70. PubMed ID: 1646986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translocation junctions cluster at the distal short arm of chromosome 1 (1p36.1-2) in human neuroblastoma cells.
    Barker PE; Savelyeva L; Schwab M
    Oncogene; 1993 Dec; 8(12):3353-8. PubMed ID: 8247537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.
    Mora J; Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Fazzari M; Heller G; Chen L; Gerald WL
    J Mol Diagn; 2000 Feb; 2(1):37-46. PubMed ID: 11272900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multiplex PCR assay for routine evaluation of deletion of the short arm of chromosome 1 in neuroblastoma.
    Schleiermacher G; Peter M; Michon J; Zucker JM; Thomas G; Magdelénat H; Delattre O
    Eur J Cancer; 1995; 31A(4):535-8. PubMed ID: 7576961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma.
    Aalto Y; Eriksson L; Seregard S; Larsson O; Knuutila S
    Invest Ophthalmol Vis Sci; 2001 Feb; 42(2):313-7. PubMed ID: 11157859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval.
    Walker GJ; Indsto JO; Sood R; Faruque MU; Hu P; Pollock PM; Duray P; Holland EA; Brown K; Kefford RF; Trent JM; Mann GJ; Hayward NK
    Genes Chromosomes Cancer; 2004 Sep; 41(1):56-64. PubMed ID: 15236317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two distinct regions involved in 1p deletion in human primary breast cancer.
    Bièche I; Champème MH; Matifas F; Cropp CS; Callahan R; Lidereau R
    Cancer Res; 1993 May; 53(9):1990-4. PubMed ID: 8097672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma.
    Holland EA; Beaton SC; Edwards BG; Kefford RF; Mann GJ
    Oncogene; 1994 May; 9(5):1361-5. PubMed ID: 8152796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromosome 9 deletion in sporadic and familial melanomas in vivo.
    Isshiki K; Seng BA; Elder DE; Guerry D; Linnenbach AJ
    Oncogene; 1994 Jun; 9(6):1649-53. PubMed ID: 8183559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis.
    Takata M; Morita R; Takehara K
    Int J Cancer; 2000 Feb; 85(4):492-7. PubMed ID: 10699920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA.
    Yang KP; Nguyen CV; Castillo SG; Samaan NA
    Anticancer Res; 1990; 10(2B):527-33. PubMed ID: 1972009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distal deletion of chromosome Ip in ductal carcinoma of the breast.
    Genuardi M; Tsihira H; Anderson DE; Saunders GF
    Am J Hum Genet; 1989 Jul; 45(1):73-82. PubMed ID: 2545098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
    Dracopoli NC; Houghton AN; Old LJ
    Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1470-4. PubMed ID: 2983346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allelotype of neuroblastoma.
    Takita J; Hayashi Y; Kohno T; Shiseki M; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
    Oncogene; 1995 Nov; 11(9):1829-34. PubMed ID: 7478611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of heterozygosity at polymorphic chromosomal loci in patients with malignant melanoma.
    Orita M; Murakami Y; Ishihara K; Sekiya T
    J Invest Dermatol; 1989 May; 92(5 Suppl):280S-283S. PubMed ID: 2565933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of heterozygosity on chromosome 1 and 9 and hormone receptor analysis of metastatic malignant melanoma presenting in breast.
    Beaty MW; Quezado M; Sobel ME; Duray P; Merino MJ
    Int J Surg Pathol; 2005 Jan; 13(1):9-18. PubMed ID: 15735850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter.
    Noll WW; Belloni DR; Rutter JL; Storm CA; Schned AR; Titus-Ernstoff L; Ernstoff MS; Brinckerhoff CE
    Am J Pathol; 2001 Feb; 158(2):691-7. PubMed ID: 11159206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma.
    Indsto JO; Nassif NT; Kefford RF; Mann GJ
    Clin Cancer Res; 2003 Dec; 9(17):6476-82. PubMed ID: 14695151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.